Work

Abstract B112: A dose escalation and cohort expansion study of the CDK9 inhibitor KB-0742 in relapsed, refractory ovarian cancer and transcriptionally addicted relapsed or refractory solid tumors

Year: 2024

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.ovarian23-b112

Authors: Miguel Villalona-Calero, Monica Mita, Alain Mita, Noah Federman, Drew Rasco, David Spigel, Jia Luo, Gregory M. Cote, Richard E. Cutler, Pavan Kumar, Crystal J. MacKenzie, Charles Lin, Jorge F. DiMartino, Elizabeth A. Olek, Brian Van Tine

Institutions: City Of Hope National Medical Center, Cedars-Sinai Medical Center, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, South Texas Accelerated Research Therapeutics, Sarah Cannon, Tennessee Oncology, Dana-Farber Cancer Institute, Massachusetts General Hospital, Washington University in St. Louis

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4392367583

Cites:

Cited by: 1

Related to: 10